Category: Upper Gastrointestinal Tract

Per-Oral Endoscopic Myotomy (POEM) Offers Critical Guidelines

A clinical practice update presented vital guidance on per-oral endoscopic myotomy (POEM), emphasizing that extensive diagnostic evaluations are essential before treatment. It highlights POEM as the preferred option for type III achalasia, while also supporting laparoscopic Heller myotomy and pneumatic dilation for other types. Antibiotic prophylaxis, post-procedure monitoring for gastroesophageal reflux disease, and individualized discharge […]

Postoperative complications significantly reduce survival in gastric cancer patients

Postoperative complications notably impact overall survival rates in gastric cancer patients. Among a cohort of 236 individuals, those experiencing complications showed a stark decrease in survival—58.1% at three years compared to 82.3% without complications. Delirium was the most common complication observed. Furthermore, non-cancer-related deaths, primarily from pneumonia, were substantially higher in patients with complications. Factors […]

Perioperative chemotherapy significantly improves survival in esophageal cancer patients

A retrospective analysis of over 57,000 patients with stage II to III esophageal cancer revealed that both perioperative chemotherapy and trimodality therapy significantly enhance overall survival compared to definitive chemoradiation therapy (DCRT). Perioperative chemotherapy showed a median overall survival of 66.2 months, while trimodality therapy had a median of 43.9 months. In contrast, patients receiving […]

Robotic gastrectomy outperforms laparoscopic for gastric cancer

A comprehensive analysis of 68,755 patients indicates that robotic gastrectomy (rg) offers superior outcomes compared to laparoscopic gastrectomy (lg) in gastric cancer treatment. Key benefits of rg include increased lymph node retrieval, reduced intraoperative blood loss, shorter hospital stays, and faster recovery metrics, such as time to first flatus and oral intake. Although rg is […]

Predictive model for pathologic complete response in esophageal cancer

A new predictive model, combining small ribonucleic acids (srnas) and clinical factors, shows promise in forecasting pathologic complete response (pcr) in esophageal squamous cell carcinoma post-neoadjuvant chemoradiotherapy. Among 99 patients, significant predictors included isomirs of let-7b and mir-93, plus specific clinical indicators. The model achieved an area under the curve of 0.84, suggesting its potential […]

Sigmoid-type achalasia shows higher risk of esophageal cancer

In a study involving 450 achalasia patients undergoing peroral endoscopic myotomy (POEM), treatment outcomes were favorable across disease types, with efficacy rates of 97.9% and 94.2% at one and two years, respectively. However, the incidence of esophageal cancer varied significantly among types: 1% in straight, 2.5% in sigmoid type 1, and 10% in sigmoid type […]

Neoadjuvant therapies are increasingly used for gastric adenocarcinoma.

A significant increase in the utilization of neoadjuvant therapies, particularly neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NCRT), was observed from 2012 to 2017 among gastric adenocarcinoma patients. The analysis included 25,073 patients, revealing median overall survival rates of 51.0 months for those receiving neoadjuvant therapy versus 42.4 months for adjuvant therapy and 38.0 months for […]

Tumor-stroma percentage predicts survival in gastric cancer patients

A predictive model utilizing tumor-stroma percentage (tsp) in gastric cancer (gc) demonstrated its significance as an adverse prognostic factor for overall survival (OS). Among 872 gc patients, tsp-visual showed a hazard ratio of 2.042, indicating a correlation with advanced pathological staging. The developed nomogram effectively identified patients at risk for poor prognosis, while a novel […]

Surgery improves outcomes in metastatic neuroendocrine tumors

Evidence suggests that surgical intervention, prior to peptide receptor radionuclide therapy, significantly enhances progression-free survival for patients with metastatic gastroenteropancreatic neuroendocrine tumors. In a study of 89 well-matched patients, those who underwent surgery had a median progression-free survival of 26.1 months, compared to 15.6 months in the no-surgery group (p = .04). Furthermore, liver debulking […]

Lymph node ratio predicts survival in duodenal adenocarcinoma

The lymph node ratio (LNR) has been identified as a crucial prognostic factor in patients with postoperative duodenal adenocarcinoma. In a study involving 943 patients, those with an LNR of 0.12 or greater experienced poorer overall survival. A nomogram integrating key prognostic factors, including LNR and tumor size, provided effective risk stratification. High-risk patients benefited […]